Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 6/20 | 0.62 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.61 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 4/20 | 0.57 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | HRH2 | P25021 | 2/20 | 0.57 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.57 |
| ▸ | DRD4 | P21917 | 2/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.57 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.57 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | HTR1B | P28222 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.57 |
| ▸ | HTR2B | P41595 | 1/20 | 0.57 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5810188 | 0.87 | SCN4A (0.61) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL3435133 | 0.87 | SCN4A (0.61) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL5810193 | 0.87 | SCN4A (0.61) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL14399414 | 0.87 | DRD3 (0.58) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| Bromide SCHEMBL4631988 | 0.86 | SCN4A (0.60) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| Bromide SCHEMBL1234856 | 0.86 | SCN4A (0.60) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL31214169 | 0.86 | SCN4A (0.67) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL17156950 | 0.84 | SCN3A (0.48) | SCN4ASCN3ASCN9ASCN5A | |
| SCHEMBL10053499 | 0.83 | SCN4A (0.58) | SCN4ASCN3ASCN9ASCN5ADRD3 | |
| SCHEMBL10053497 | 0.83 | SCN4A (0.58) | SCN4ASCN3ASCN9ASCN5ADRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-03-14 | — | — | US | disclosed |
| EP-4263547-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | Chiesi Farmaceutici S.p.A. (IT) | 2023-10-25 | — | — | EP | disclosed |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | SYNGENE INTERNATIONAL LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| WO-2022128853-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2022-06-23 | — | — | WO | disclosed |
| WO-2021087181-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-05-06 | — | — | WO | disclosed |
| US-20100197679-A1 | COMPOUNDS | GLAXO GROUP LIMITED | 2010-08-05 | — | — | US | disclosed |
| EP-2139898-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008128961-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-10-30 | — | — | WO | disclosed |
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1640369-A1 | THIAZOLIMINE COMPOUND AND OXAZOLIMINE COMPOUND | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197679-A1 | COMPOUNDS | NRDC, MRPL21, NISCH | SCN4A 3401/4885SCN3A 3139/4885SCN9A 2168/4885 |
| US-20070105908-A1 | Thiazolimine compound and oxazolimine compound | CMA1, TH, NPR3 | SCN4A 3147/4885SCN3A 874/4885SCN9A 2207/4885 |
| US-20240082223-A1 | DIHYDROFUROPYRIDINE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, RHOA | SCN4A 3282/4885SCN3A 3364/4885SCN9A 3293/4885 |
| US-20230117470-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS AS TOLL RECEPTOR INHIBITORS | TLR1, TLR3, TLR9 | SCN4A 2657/4885SCN3A 2184/4885SCN9A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.